Company: JSKJ
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001477932-25-008401
Chunk: 7

Company: Jiansu (Shanghai) Information Technology Co., Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 7
---
idends and Other Distributions.”

|                                           |     | Per Share |     |     | Total |     |
|:------------------------------------------|:----|:----------|:----|:----|:------|:----|
| Initial public offering price(1)          |     | $         | [●] |     | $     | [●] |
| Underwriting discounts and commissions(2) |     | $         | [●] |     | $     | [●] |
| Proceeds to us, before expenses           |     | $         | [●] |     | $     | [●] |

| (1) | Based on an assumed public offering price of US$[●] per ordinary share.                                       |
| (2) | Represents underwriting discount and commissions equal to 8% per ordinary share (or $[●] per ordinary share). |

Does not include the following additional compensation payable to the underwriters. In addition to the compensation referenced above, we have agreed to provide [●], the representative of the underwriters, or their designees, with a non-accountable expense allowance equal to 0.5% of the gross proceeds of this offering, payable to the underwriters, or the reimbursement of certain expenses of the underwriters. In addition, we have agreed to issue upon the closing of this offering, compensation warrants to [●], as representative of the underwriters, exercisable for a one and a half year period commencing six months from the commencement date of sales in this offering entitling the representative to purchase up to 5% of the number of shares sold in this offering at a per share exercise price equal to the public offering price. The registration statement of which this prospectus is a part also covers such warrants and the shares issuable upon the exercise thereof. For a description of the other terms of compensation to be received by the underwriters, see “ Underwriting.”

We have granted the representative of the underwriters an option for a period of 30 days to purchase up to an additional [●] ordinary shares, solely to cover over-allotments, if any.

Neither the U.S. Securities and Exchange Commission (the “SEC”) nor any other regulatory body has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

The underwriters expect to deliver the ordinary shares against payment in New York, NY on or about [●], 2025.

<div